Outro Health: The People Behind Antidepressant Tapering Care

People who struggled to stop antidepressants helped supply the knowledge Outro Health is organizing into clinical care. The New York virtual clinic, led by co-founder and CEO Brandon Goode with co-founder Dr. Mark Horowitz, specializes in clinician-supervised tapering for patients considering medication reduction with professional support.

Outro combines individualized plans, monitoring, clinical follow-up and prescription coordination. The company reports availability in 14 U.S. states and lists its program at $225/month. Its recently announced $7M across pre-seed and seed rounds gives the company resources to expand a specialist care model whose delivery depends on trained people as well as software.

How Outro turns tapering into an ongoing service

Outro's service begins with clinical evaluation and continues through an individualized plan, follow-up and adjustment. Its program guide describes symptom tracking and journaling, clinician and care-coordinator messaging, custom prescriptions and peer support. These functions give the care team several ways to learn how the patient is doing between appointments.

The company describes its approach as hyperbolic tapering, with smaller dose reductions toward the lower end of a taper. Medication choice, timing and adjustment remain matters for a patient and qualified clinician. Follow-up lets the clinician respond to the individual experience instead of treating the initial plan as the end of the work.

The service's structure puts different responsibilities next to each other. A digital portal can collect information, a prescription can provide a particular formulation and a clinician can interpret a change in symptoms. The experience depends on those pieces reaching the same patient in a coordinated way, rather than simply existing somewhere inside the company.

NICE's guidance on stopping antidepressants recommends agreed staged reduction and monitoring for withdrawal and returning depression symptoms. That independent guidance helps explain why follow-up is part of the work. It also supplies a useful distinction for readers evaluating the company: the clinical rationale for supervised reduction and evidence of Outro's own patient outcomes are separate questions.

A founding team shaped by research and patient advocacy

Brandon Goode's account of the company's origins starts with work in interventional psychiatry and an unexpected need among people seeking care. Patients were looking for help discontinuing existing antidepressants. That observation directed his attention toward a service built around medication review and supported reduction.

Mark Horowitz brought research into psychiatric medication withdrawal and personal experience of the difficulty of stopping treatment. His official biography identifies him as a co-founder and lead author of The Maudsley Deprescribing Guidelines. His work connects the company to a body of research on how people experience medication withdrawal.

A 2023 founder interview describes Tyler Dyck and Adele Framer as part of the founding team alongside Goode and Horowitz. Framer's current company biography lists her as Patient Advisor and records her establishment of Surviving Antidepressants, a peer-support resource. The current leadership page leaves Dyck's operating role unspecified, while Framer's advisory role remains visible.

The current team page also lists Bryan Shapiro as senior medical advisor. Together, the visible roles show the kinds of knowledge the service brings together: company building, clinical research, medical advice and patient advocacy. For a service built around patient updates, that range of experience gives the team several ways to understand what a person is reporting.

The business model and the technology supporting it

Outro's posted $225/month program price makes time an explicit part of the commercial model. A patient may need recurring care over a changing period, so price and duration both matter to access. Patients still need to confirm medication costs and any applicable reimbursement with the service and their insurer.

The company announced $7M across pre-seed and seed rounds on October 8, 2026, naming Listen Ventures, Cake Ventures, LAUNCH, Actions Capital, Hannah Grey VC, SemperVirens, Brock Recovery Group and Pave Health Ventures among participants. The announcement does not disclose a lead, the allocation between the rounds or a valuation. Its stated priorities include clinician capacity, workflow development, additional medication classes and academic and advocacy relationships.

One concrete technology disclosure sits in Outro's telehealth consent policy. The policy describes Heidi preparing a clinical note or summary that a clinician reviews before it enters the medical record. The disclosed tool supports documentation, with a named human review step before the note becomes part of the patient record.

For operators evaluating this business, documentation and coordination are useful places to look because they consume attention the service also needs for clinical work. Public materials do not establish revenue, enrollment, margins or independently validated outcomes. The visible model offers a clear description of what must be delivered, while leaving its financial efficiency and comparative clinical performance open to further evidence.

What current recruitment reveals about the company

Outro's official careers board, linked from a company biography, provides a more specific workforce signal than a general claim that a startup is growing. At the October 8 readback, it listed remote psychiatric practitioner roles, marketing and operations application channels, and a general open application. Those entries do not translate directly into a headcount target.

The California practitioner listing specifies active PMHNP certification, California licensure and at least 2 years of post-certification experience. Its responsibilities include evaluations, individualized plans, continuing care and collaboration with care coordinators. The listing describes a 1099 arrangement for that role; it should not be generalized to every person working at Outro.

The operations application invites operators and clinical operators to explore whether their skills and timing fit the company. Applicants are being invited into a conversation about a potential fit, with no specific vacancy promised in that channel. The current board and the separately linked provider-interest form offer practical starting points for people whose skills match the service.

The recruitment record makes the specialist nature of Outro's work legible. The company needs people who can translate patient updates into assessments, coordinate the next practical step and remain accountable inside a remote care setting. As its coverage and services develop, the work described in those clinical roles will remain close to the patient's changing experience of treatment.